Antiviral_Drugs.ppt

Dr Sumitha Jagadibabu
Dr Sumitha JagadibabuAssociate Professor en JBAS College for Women
ANTiviral drugs
CHEnnai
Dr Sumitha J
Antiviral agents
• Antiviral agents are medications used to treat viral infections
by inhibiting the replication of viruses or reducing their
ability to cause disease.
Types of Antiviral Agents
• Antiviral agents can be classified into several categories based on their mechanism of action:
• Entry Inhibitors: These drugs prevent the virus from entering host cells. Examples include fusion
inhibitors and attachment inhibitors.
• Nucleoside/Nucleotide Analogues: These drugs mimic the building blocks of DNA or RNA and
interfere with viral replication. Examples include acyclovir and tenofovir.
• Protease Inhibitors: These drugs target viral proteases required for viral replication. They are
commonly used in treating HIV and hepatitis C.
• Polymerase Inhibitors: These drugs inhibit viral enzymes (e.g., reverse transcriptase,
polymerase) involved in replicating the viral genome. Examples include zidovudine and
sofosbuvir.
• Neuraminidase Inhibitors: These drugs inhibit neuraminidase, an enzyme necessary for the
release of new virus particles. Oseltamivir is a well-known example.
Mechanism of Action
• antiviral agents interfere with specific stages of the viral life
cycle, including attachment, entry, replication, and release
Mechanism of Action
Attachment Inhibition: Viruses must first attach to specific receptors on
the surface of host cells to initiate infection. Antiviral agents can
interfere with this attachment process by:
• Competitive Binding: These agents mimic host cell receptors and compete with the virus for
binding sites. When the virus binds to the antiviral agent instead of the host cell receptor, it can't
initiate infection.
• Blocking Receptor Sites: Some drugs block or mask the viral binding sites on host cells, preventing
the virus from attaching.
Mechanism of Action
Entry Inhibition:After attachment, the virus needs to enter the host cell.
Antiviral agents can interfere with this step by:
• Fusion Inhibition: Fusion inhibitors, like enfuvirtide for HIV, block the fusion of viral and cellular
membranes, preventing the virus from entering the host cell.
• Endocytosis Inhibition: Some antiviral drugs can inhibit the endocytosis process that viruses use
to enter cells.
Mechanism of Action
Replication Inhibition: Once inside the host cell, viruses use the host's
machinery to replicate their genetic material and produce new viral
particles. Antiviral agents can disrupt this replication process by
targeting:
• Nucleoside/Nucleotide Analogues: These drugs resemble the building blocks of DNA or RNA and get
incorporated into the viral genome during replication, causing mutations and preventing further
replication. Examples include acyclovir and tenofovir.
• Protease Inhibitors: These drugs target viral proteases required for processing viral proteins,
preventing the formation of functional viral particles. They are commonly used in treating HIV and
hepatitis C.
• Polymerase Inhibitors: These drugs inhibit viral enzymes (e.g., reverse transcriptase, polymerase)
involved in replicating the viral genome.
Mechanism of Action
Release Inhibition:After replication, viruses must exit the host
cell to spread and infect other cells. Antiviral agents can
interfere with this release step by:
• Neuraminidase Inhibition: Neuraminidase is an enzyme required for the release of new
virus particles from host cells. Inhibiting this enzyme prevents the release of viruses.
Oseltamivir (Tamiflu) is an example used for influenza.
Selectivity and Resistance
• Selectivity of Antiviral Agents:
• Antiviral agents are designed to specifically target viral
processes, such as attachment, replication, or release, without
interfering with normal host cell functions. This selectivity is
essential for minimizing side effects and preserving the health of
the host.
• Selectivity is achieved by identifying unique viral targets or
processes that are distinct from those found in host cells. For
example, targeting viral enzymes or proteins that have no direct
equivalent in human cells.
• By specifically interfering with viral processes, antiviral agents
aim to disrupt the viral life cycle while leaving host cell functions
• Development of Drug Resistance:
• Viruses can develop resistance to antiviral agents over time due to
genetic mutations. This phenomenon is similar to the development of
antibiotic resistance in bacteria.
• When antiviral agents are used to treat viral infections, some viruses
may acquire mutations in their genetic material that confer resistance
to the drug. These mutations can occur naturally during viral
replication.
• Drug-resistant viral variants have changes in their viral targets (e.g.,
enzymes or proteins) that reduce the drug's ability to bind or inhibit
the viral process effectively. As a result, the drug becomes less
effective or completely ineffective against the resistant virus.
• The emergence of drug-resistant viruses is a significant concern in
Side effetcts
• Gastrointestinal Disturbances: Many antiviral drugs can cause
gastrointestinal side effects, including nausea, vomiting, diarrhea, or
abdominal discomfort. Patients should be advised to take these
medications with food or as directed to minimize these effects.
• Fatigue: Fatigue is a common side effect of antiviral therapy.
Patients may experience decreased energy levels and overall
tiredness.
• Headache: Headaches are often reported by individuals taking
antiviral drugs, particularly during the initial stages of treatment.
• Skin Reactions: Some antiviral drugs can lead to skin reactions,
such as rashes, itching, or hypersensitivity reactions. Patients
Side effetcts
• Liver and Kidney Function: Certain antiviral drugs can affect liver or
kidney function. Monitoring liver enzyme levels and kidney function
through blood tests is essential to detect any abnormalities early.
• Hematological Effects: Some antiviral drugs can cause
hematological side effects, including anemia, neutropenia (low white
blood cell count), or thrombocytopenia (low platelet count). Regular
blood tests are necessary to monitor these parameters.
• Psychiatric Symptoms: In some cases, antiviral therapy can lead to
mood changes or psychiatric symptoms. Patients and caregivers
should be educated about these potential side effects and
encouraged to seek help if necessary
Antiviral_Drugs.ppt
Case Studies
• Case Study 1:Patient Scenario:
• A 28-year-old sexually active male presents with symptoms
of painful genital sores and flu-like symptoms. He has a
history of multiple sexual partners and has not been
consistently using protection. A clinical evaluation and
testing confirm a diagnosis of genital herpes (HSV-2
infection).
Group Activity
• Review the patient's medical history, symptoms, and
diagnostic results.
• Discuss the mechanisms of action of antiviral drugs used to
treat HSV infections.
• Recommend an appropriate antiviral treatment, including
the drug name, dosage, and duration of therapy.
• Consider the importance of patient education regarding
transmission prevention and managing recurrent outbreaks.
Case Studies
• Case Study 2:Patient Scenario:
• A 55-year-old patient with a history of intravenous drug use
presents with persistent fatigue, abdominal pain, and dark urine.
Laboratory tests show elevated liver enzymes, and further testing
confirms a chronic hepatitis C infection.
Group Activity
• Explore the mechanisms of action of antiviral drugs used to treat
chronic hepatitis C.
• Consider the patient's medical history, current symptoms, and
liver function tests.
• Recommend an appropriate antiviral treatment regimen,
including specific antiviral drugs, their doses, and duration.
• Discuss the potential side effects and drug interactions and how
to monitor and manage them.
• Highlight the importance of adherence and regular monitoring to
assess treatment response.
CASE STUDIES
• Case Study 3:Patient Scenario:
• A 45-year-old healthcare worker tests positive for COVID-19.
The patient is mildly symptomatic with fever, cough, and
fatigue. They have no known allergies or significant
comorbidities.
Group Activity
• Research and discuss the available antiviral treatments for
COVID-19.
• Consider the patient's mild symptoms, occupation, and
comorbidities.
• Recommend an appropriate antiviral treatment strategy,
including specific drugs (if applicable), dosages, and
duration.
• Discuss potential side effects and monitoring parameters for
COVID-19 treatment.
• Emphasize the importance of isolation, infection control
1 de 19

Recomendados

HICC.pdf por
HICC.pdfHICC.pdf
HICC.pdfDr Sumitha Jagadibabu
215 vistas3 diapositivas
Rubella Virus.pptx por
Rubella Virus.pptxRubella Virus.pptx
Rubella Virus.pptxDr Sumitha Jagadibabu
135 vistas13 diapositivas
Rhabdo Virus.pptx por
Rhabdo Virus.pptxRhabdo Virus.pptx
Rhabdo Virus.pptxDr Sumitha Jagadibabu
112 vistas17 diapositivas
HAI.pdf por
HAI.pdfHAI.pdf
HAI.pdfDr Sumitha Jagadibabu
163 vistas2 diapositivas
Corona Virus.pptx por
Corona Virus.pptxCorona Virus.pptx
Corona Virus.pptxDr Sumitha Jagadibabu
154 vistas19 diapositivas
Lect no.1 a introduction to virology-gen.prop and class por
Lect no.1 a introduction to virology-gen.prop and classLect no.1 a introduction to virology-gen.prop and class
Lect no.1 a introduction to virology-gen.prop and classMahomed Mahomed
3.3K vistas27 diapositivas

Más contenido relacionado

La actualidad más candente

Paramyxoviruses por
ParamyxovirusesParamyxoviruses
ParamyxovirusesDr. Rakesh Prasad Sah
1.2K vistas31 diapositivas
Myxovirus MICROBIOLOGY REVISION por
Myxovirus MICROBIOLOGY REVISIONMyxovirus MICROBIOLOGY REVISION
Myxovirus MICROBIOLOGY REVISIONTONY SCARIA
1.7K vistas36 diapositivas
Antivirals, interferon and vaccines lect copy por
Antivirals, interferon and vaccines lect   copyAntivirals, interferon and vaccines lect   copy
Antivirals, interferon and vaccines lect copyMD Specialclass
4K vistas50 diapositivas
Virology introduction mbbs por
Virology introduction mbbsVirology introduction mbbs
Virology introduction mbbsShyam Mishra
2.5K vistas28 diapositivas
Orthomyxoviruses... por
Orthomyxoviruses...Orthomyxoviruses...
Orthomyxoviruses...Akshmala Sharma
509 vistas31 diapositivas
Pathogenesis Virus por
Pathogenesis VirusPathogenesis Virus
Pathogenesis Virusraj kumar
24.2K vistas26 diapositivas

La actualidad más candente(20)

Myxovirus MICROBIOLOGY REVISION por TONY SCARIA
Myxovirus MICROBIOLOGY REVISIONMyxovirus MICROBIOLOGY REVISION
Myxovirus MICROBIOLOGY REVISION
TONY SCARIA 1.7K vistas
Antivirals, interferon and vaccines lect copy por MD Specialclass
Antivirals, interferon and vaccines lect   copyAntivirals, interferon and vaccines lect   copy
Antivirals, interferon and vaccines lect copy
MD Specialclass4K vistas
Virology introduction mbbs por Shyam Mishra
Virology introduction mbbsVirology introduction mbbs
Virology introduction mbbs
Shyam Mishra2.5K vistas
Pathogenesis Virus por raj kumar
Pathogenesis VirusPathogenesis Virus
Pathogenesis Virus
raj kumar24.2K vistas
Human retroviruses por ankit
Human retroviruses Human retroviruses
Human retroviruses
ankit 31.5K vistas
Reoviruses/Reoviridae and Rotavirus por Fadi Marroushi
Reoviruses/Reoviridae and RotavirusReoviruses/Reoviridae and Rotavirus
Reoviruses/Reoviridae and Rotavirus
Fadi Marroushi9.2K vistas
Classification of virus por saran96
Classification of virusClassification of virus
Classification of virus
saran969.8K vistas

Similar a Antiviral_Drugs.ppt

Chp no 2 anti-microbial.pptx por
Chp no 2 anti-microbial.pptxChp no 2 anti-microbial.pptx
Chp no 2 anti-microbial.pptxMahnoorFatima92
5 vistas21 diapositivas
Antibiotic policy por
Antibiotic policyAntibiotic policy
Antibiotic policyMona Mustafa
13.7K vistas40 diapositivas
Antibiotic policy por
Antibiotic policyAntibiotic policy
Antibiotic policywisam alsaedi
556 vistas40 diapositivas
ANTIVIRAL DRUGS.ppt por
ANTIVIRAL DRUGS.pptANTIVIRAL DRUGS.ppt
ANTIVIRAL DRUGS.pptAbwoneKenneth
28 vistas103 diapositivas
Antibiotic Resistance & stewardship program in children por
Antibiotic  Resistance & stewardship program in childrenAntibiotic  Resistance & stewardship program in children
Antibiotic Resistance & stewardship program in childrenAzad Haleem
2.3K vistas32 diapositivas
Immunotherapy of tumor por
Immunotherapy of tumorImmunotherapy of tumor
Immunotherapy of tumorsountharya Sen s
243 vistas18 diapositivas

Similar a Antiviral_Drugs.ppt(20)

Antibiotic policy por Mona Mustafa
Antibiotic policyAntibiotic policy
Antibiotic policy
Mona Mustafa13.7K vistas
Antibiotic Resistance & stewardship program in children por Azad Haleem
Antibiotic  Resistance & stewardship program in childrenAntibiotic  Resistance & stewardship program in children
Antibiotic Resistance & stewardship program in children
Azad Haleem2.3K vistas
Antibiotic; introduction & stewardship program in children por Azad Haleem
Antibiotic; introduction & stewardship program in childrenAntibiotic; introduction & stewardship program in children
Antibiotic; introduction & stewardship program in children
Azad Haleem4.8K vistas
Rational use of antibiotics por ZeelNaik2
Rational use of antibioticsRational use of antibiotics
Rational use of antibiotics
ZeelNaik2104 vistas
Antibiotics antiviral drugs used in HSV I & II , DRUGS USED IN HIV. por Vinitkumar MJ
Antibiotics antiviral drugs used in HSV I & II , DRUGS USED IN HIV.Antibiotics antiviral drugs used in HSV I & II , DRUGS USED IN HIV.
Antibiotics antiviral drugs used in HSV I & II , DRUGS USED IN HIV.
Vinitkumar MJ202 vistas
0VERVIEW OF ANTIBIOTIC RESISTANCE 111.pptx por KrishnaSupalkar
0VERVIEW OF ANTIBIOTIC RESISTANCE 111.pptx0VERVIEW OF ANTIBIOTIC RESISTANCE 111.pptx
0VERVIEW OF ANTIBIOTIC RESISTANCE 111.pptx
KrishnaSupalkar220 vistas
Principle of antibiotic use.pptx por Olofin Kayode
Principle of antibiotic use.pptxPrinciple of antibiotic use.pptx
Principle of antibiotic use.pptx
Olofin Kayode3 vistas
Prinicple of Anti microbial therapy dr.kanwar singh.ppt por UnnayanRaj
Prinicple of Anti microbial therapy dr.kanwar singh.pptPrinicple of Anti microbial therapy dr.kanwar singh.ppt
Prinicple of Anti microbial therapy dr.kanwar singh.ppt
UnnayanRaj10 vistas
Hepatitis.ppt por Alick12
Hepatitis.pptHepatitis.ppt
Hepatitis.ppt
Alick123 vistas

Más de Dr Sumitha Jagadibabu

Structure,Function and Properties of Immune cells.pdf por
Structure,Function and Properties of Immune cells.pdfStructure,Function and Properties of Immune cells.pdf
Structure,Function and Properties of Immune cells.pdfDr Sumitha Jagadibabu
9 vistas12 diapositivas
ARBO Viruses.pdf por
ARBO Viruses.pdfARBO Viruses.pdf
ARBO Viruses.pdfDr Sumitha Jagadibabu
9 vistas12 diapositivas
TOXINS.pptx por
TOXINS.pptxTOXINS.pptx
TOXINS.pptxDr Sumitha Jagadibabu
12 vistas17 diapositivas
Paramyxovirus.pptx por
Paramyxovirus.pptxParamyxovirus.pptx
Paramyxovirus.pptxDr Sumitha Jagadibabu
6 vistas12 diapositivas
Orthomyxovirus.pptx por
Orthomyxovirus.pptxOrthomyxovirus.pptx
Orthomyxovirus.pptxDr Sumitha Jagadibabu
14 vistas16 diapositivas
Microbial Pathogenicity.pptx por
Microbial Pathogenicity.pptxMicrobial Pathogenicity.pptx
Microbial Pathogenicity.pptxDr Sumitha Jagadibabu
86 vistas39 diapositivas

Más de Dr Sumitha Jagadibabu(20)

Último

"How can I develop my learning path in bioinformatics? por
"How can I develop my learning path in bioinformatics?"How can I develop my learning path in bioinformatics?
"How can I develop my learning path in bioinformatics?Bioinformy
21 vistas13 diapositivas
A Ready-to-Analyze High-Plex Spatial Signature Development Workflow for Cance... por
A Ready-to-Analyze High-Plex Spatial Signature Development Workflow for Cance...A Ready-to-Analyze High-Plex Spatial Signature Development Workflow for Cance...
A Ready-to-Analyze High-Plex Spatial Signature Development Workflow for Cance...InsideScientific
43 vistas62 diapositivas
Nitrosamine & NDSRI.pptx por
Nitrosamine & NDSRI.pptxNitrosamine & NDSRI.pptx
Nitrosamine & NDSRI.pptxNileshBonde4
9 vistas22 diapositivas
plasmids por
plasmidsplasmids
plasmidsscribddarkened352
7 vistas2 diapositivas
Pollination By Nagapradheesh.M.pptx por
Pollination By Nagapradheesh.M.pptxPollination By Nagapradheesh.M.pptx
Pollination By Nagapradheesh.M.pptxMNAGAPRADHEESH
15 vistas9 diapositivas
PRINCIPLES-OF ASSESSMENT por
PRINCIPLES-OF ASSESSMENTPRINCIPLES-OF ASSESSMENT
PRINCIPLES-OF ASSESSMENTrbalmagro
11 vistas12 diapositivas

Último(20)

"How can I develop my learning path in bioinformatics? por Bioinformy
"How can I develop my learning path in bioinformatics?"How can I develop my learning path in bioinformatics?
"How can I develop my learning path in bioinformatics?
Bioinformy21 vistas
A Ready-to-Analyze High-Plex Spatial Signature Development Workflow for Cance... por InsideScientific
A Ready-to-Analyze High-Plex Spatial Signature Development Workflow for Cance...A Ready-to-Analyze High-Plex Spatial Signature Development Workflow for Cance...
A Ready-to-Analyze High-Plex Spatial Signature Development Workflow for Cance...
InsideScientific43 vistas
Pollination By Nagapradheesh.M.pptx por MNAGAPRADHEESH
Pollination By Nagapradheesh.M.pptxPollination By Nagapradheesh.M.pptx
Pollination By Nagapradheesh.M.pptx
MNAGAPRADHEESH15 vistas
PRINCIPLES-OF ASSESSMENT por rbalmagro
PRINCIPLES-OF ASSESSMENTPRINCIPLES-OF ASSESSMENT
PRINCIPLES-OF ASSESSMENT
rbalmagro11 vistas
Connecting communities to promote FAIR resources: perspectives from an RDA / ... por Allyson Lister
Connecting communities to promote FAIR resources: perspectives from an RDA / ...Connecting communities to promote FAIR resources: perspectives from an RDA / ...
Connecting communities to promote FAIR resources: perspectives from an RDA / ...
Allyson Lister34 vistas
Workshop Chemical Robotics ChemAI 231116.pptx por Marco Tibaldi
Workshop Chemical Robotics ChemAI 231116.pptxWorkshop Chemical Robotics ChemAI 231116.pptx
Workshop Chemical Robotics ChemAI 231116.pptx
Marco Tibaldi95 vistas
ENTOMOLOGY PPT ON BOMBYCIDAE AND SATURNIIDAE.pptx por MN
ENTOMOLOGY PPT ON BOMBYCIDAE AND SATURNIIDAE.pptxENTOMOLOGY PPT ON BOMBYCIDAE AND SATURNIIDAE.pptx
ENTOMOLOGY PPT ON BOMBYCIDAE AND SATURNIIDAE.pptx
MN6 vistas
A training, certification and marketing scheme for informal dairy vendors in ... por ILRI
A training, certification and marketing scheme for informal dairy vendors in ...A training, certification and marketing scheme for informal dairy vendors in ...
A training, certification and marketing scheme for informal dairy vendors in ...
ILRI11 vistas
Conventional and non-conventional methods for improvement of cucurbits.pptx por gandhi976
Conventional and non-conventional methods for improvement of cucurbits.pptxConventional and non-conventional methods for improvement of cucurbits.pptx
Conventional and non-conventional methods for improvement of cucurbits.pptx
gandhi97618 vistas
Experimental animal Guinea pigs.pptx por Mansee Arya
Experimental animal Guinea pigs.pptxExperimental animal Guinea pigs.pptx
Experimental animal Guinea pigs.pptx
Mansee Arya13 vistas
CSF -SHEEBA.D presentation.pptx por SheebaD7
CSF -SHEEBA.D presentation.pptxCSF -SHEEBA.D presentation.pptx
CSF -SHEEBA.D presentation.pptx
SheebaD711 vistas
MODULE-9-Biotechnology, Genetically Modified Organisms, and Gene Therapy.pdf por KerryNuez1
MODULE-9-Biotechnology, Genetically Modified Organisms, and Gene Therapy.pdfMODULE-9-Biotechnology, Genetically Modified Organisms, and Gene Therapy.pdf
MODULE-9-Biotechnology, Genetically Modified Organisms, and Gene Therapy.pdf
KerryNuez121 vistas
How to be(come) a successful PhD student por Tom Mens
How to be(come) a successful PhD studentHow to be(come) a successful PhD student
How to be(come) a successful PhD student
Tom Mens460 vistas

Antiviral_Drugs.ppt

  • 2. Antiviral agents • Antiviral agents are medications used to treat viral infections by inhibiting the replication of viruses or reducing their ability to cause disease.
  • 3. Types of Antiviral Agents • Antiviral agents can be classified into several categories based on their mechanism of action: • Entry Inhibitors: These drugs prevent the virus from entering host cells. Examples include fusion inhibitors and attachment inhibitors. • Nucleoside/Nucleotide Analogues: These drugs mimic the building blocks of DNA or RNA and interfere with viral replication. Examples include acyclovir and tenofovir. • Protease Inhibitors: These drugs target viral proteases required for viral replication. They are commonly used in treating HIV and hepatitis C. • Polymerase Inhibitors: These drugs inhibit viral enzymes (e.g., reverse transcriptase, polymerase) involved in replicating the viral genome. Examples include zidovudine and sofosbuvir. • Neuraminidase Inhibitors: These drugs inhibit neuraminidase, an enzyme necessary for the release of new virus particles. Oseltamivir is a well-known example.
  • 4. Mechanism of Action • antiviral agents interfere with specific stages of the viral life cycle, including attachment, entry, replication, and release
  • 5. Mechanism of Action Attachment Inhibition: Viruses must first attach to specific receptors on the surface of host cells to initiate infection. Antiviral agents can interfere with this attachment process by: • Competitive Binding: These agents mimic host cell receptors and compete with the virus for binding sites. When the virus binds to the antiviral agent instead of the host cell receptor, it can't initiate infection. • Blocking Receptor Sites: Some drugs block or mask the viral binding sites on host cells, preventing the virus from attaching.
  • 6. Mechanism of Action Entry Inhibition:After attachment, the virus needs to enter the host cell. Antiviral agents can interfere with this step by: • Fusion Inhibition: Fusion inhibitors, like enfuvirtide for HIV, block the fusion of viral and cellular membranes, preventing the virus from entering the host cell. • Endocytosis Inhibition: Some antiviral drugs can inhibit the endocytosis process that viruses use to enter cells.
  • 7. Mechanism of Action Replication Inhibition: Once inside the host cell, viruses use the host's machinery to replicate their genetic material and produce new viral particles. Antiviral agents can disrupt this replication process by targeting: • Nucleoside/Nucleotide Analogues: These drugs resemble the building blocks of DNA or RNA and get incorporated into the viral genome during replication, causing mutations and preventing further replication. Examples include acyclovir and tenofovir. • Protease Inhibitors: These drugs target viral proteases required for processing viral proteins, preventing the formation of functional viral particles. They are commonly used in treating HIV and hepatitis C. • Polymerase Inhibitors: These drugs inhibit viral enzymes (e.g., reverse transcriptase, polymerase) involved in replicating the viral genome.
  • 8. Mechanism of Action Release Inhibition:After replication, viruses must exit the host cell to spread and infect other cells. Antiviral agents can interfere with this release step by: • Neuraminidase Inhibition: Neuraminidase is an enzyme required for the release of new virus particles from host cells. Inhibiting this enzyme prevents the release of viruses. Oseltamivir (Tamiflu) is an example used for influenza.
  • 9. Selectivity and Resistance • Selectivity of Antiviral Agents: • Antiviral agents are designed to specifically target viral processes, such as attachment, replication, or release, without interfering with normal host cell functions. This selectivity is essential for minimizing side effects and preserving the health of the host. • Selectivity is achieved by identifying unique viral targets or processes that are distinct from those found in host cells. For example, targeting viral enzymes or proteins that have no direct equivalent in human cells. • By specifically interfering with viral processes, antiviral agents aim to disrupt the viral life cycle while leaving host cell functions
  • 10. • Development of Drug Resistance: • Viruses can develop resistance to antiviral agents over time due to genetic mutations. This phenomenon is similar to the development of antibiotic resistance in bacteria. • When antiviral agents are used to treat viral infections, some viruses may acquire mutations in their genetic material that confer resistance to the drug. These mutations can occur naturally during viral replication. • Drug-resistant viral variants have changes in their viral targets (e.g., enzymes or proteins) that reduce the drug's ability to bind or inhibit the viral process effectively. As a result, the drug becomes less effective or completely ineffective against the resistant virus. • The emergence of drug-resistant viruses is a significant concern in
  • 11. Side effetcts • Gastrointestinal Disturbances: Many antiviral drugs can cause gastrointestinal side effects, including nausea, vomiting, diarrhea, or abdominal discomfort. Patients should be advised to take these medications with food or as directed to minimize these effects. • Fatigue: Fatigue is a common side effect of antiviral therapy. Patients may experience decreased energy levels and overall tiredness. • Headache: Headaches are often reported by individuals taking antiviral drugs, particularly during the initial stages of treatment. • Skin Reactions: Some antiviral drugs can lead to skin reactions, such as rashes, itching, or hypersensitivity reactions. Patients
  • 12. Side effetcts • Liver and Kidney Function: Certain antiviral drugs can affect liver or kidney function. Monitoring liver enzyme levels and kidney function through blood tests is essential to detect any abnormalities early. • Hematological Effects: Some antiviral drugs can cause hematological side effects, including anemia, neutropenia (low white blood cell count), or thrombocytopenia (low platelet count). Regular blood tests are necessary to monitor these parameters. • Psychiatric Symptoms: In some cases, antiviral therapy can lead to mood changes or psychiatric symptoms. Patients and caregivers should be educated about these potential side effects and encouraged to seek help if necessary
  • 14. Case Studies • Case Study 1:Patient Scenario: • A 28-year-old sexually active male presents with symptoms of painful genital sores and flu-like symptoms. He has a history of multiple sexual partners and has not been consistently using protection. A clinical evaluation and testing confirm a diagnosis of genital herpes (HSV-2 infection).
  • 15. Group Activity • Review the patient's medical history, symptoms, and diagnostic results. • Discuss the mechanisms of action of antiviral drugs used to treat HSV infections. • Recommend an appropriate antiviral treatment, including the drug name, dosage, and duration of therapy. • Consider the importance of patient education regarding transmission prevention and managing recurrent outbreaks.
  • 16. Case Studies • Case Study 2:Patient Scenario: • A 55-year-old patient with a history of intravenous drug use presents with persistent fatigue, abdominal pain, and dark urine. Laboratory tests show elevated liver enzymes, and further testing confirms a chronic hepatitis C infection.
  • 17. Group Activity • Explore the mechanisms of action of antiviral drugs used to treat chronic hepatitis C. • Consider the patient's medical history, current symptoms, and liver function tests. • Recommend an appropriate antiviral treatment regimen, including specific antiviral drugs, their doses, and duration. • Discuss the potential side effects and drug interactions and how to monitor and manage them. • Highlight the importance of adherence and regular monitoring to assess treatment response.
  • 18. CASE STUDIES • Case Study 3:Patient Scenario: • A 45-year-old healthcare worker tests positive for COVID-19. The patient is mildly symptomatic with fever, cough, and fatigue. They have no known allergies or significant comorbidities.
  • 19. Group Activity • Research and discuss the available antiviral treatments for COVID-19. • Consider the patient's mild symptoms, occupation, and comorbidities. • Recommend an appropriate antiviral treatment strategy, including specific drugs (if applicable), dosages, and duration. • Discuss potential side effects and monitoring parameters for COVID-19 treatment. • Emphasize the importance of isolation, infection control